Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 2:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 272 matching trials from the live ClinicalTrials.gov search.
Conditions
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
Interventions
fludarabine phosphate, peripheral blood stem cell transplantation, iodine I 131 tositumomab, laboratory biomarker analysis, flow cytometry, polymerase chain reaction
Drug · Procedure · Radiation + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
60 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Pituitary Tumor
Interventions
To perform RT-PCR on the tissue obtained during surgery
Other
Lead sponsor
Cook County Health
Government
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Leukemia
Interventions
loss of heterozygosity analysis, microarray analysis, polymorphism analysis, tumor replication error analysis
Genetic
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Disseminated Neuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4S Neuroblastoma
Interventions
laboratory biomarker analysis, polymerase chain reaction, polyacrylamide gel electrophoresis, DNA analysis
Other · Genetic
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Monrovia, California
Conditions
HIV Infections
Interventions
Chlorhexidine gluconate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2007
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Conditions
Leukemia
Interventions
bcr-abl peptide vaccine, reverse transcriptase-polymerase chain reaction
Biological · Genetic
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Urinary Tract Infection Complicated, Urinary Tract Infection (cUTI), Urinary Tract Infection (Diagnosis)
Interventions
Treatment guided by the PCR results, Treatment guided by the C&S results
Diagnostic Test
Lead sponsor
Doc Lab Inc
Industry
Eligibility
18 Years and older
Enrollment
773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
San Jose, California • Albany, Georgia • Evans, Georgia + 3 more
Conditions
Aplastic Anemia
Interventions
cyclophosphamide, anti-thymocyte globulin, cyclosporine, allogeneic bone marrow transplantation, methotrexate, DNA analysis, flow cytometry, polymorphism analysis, laboratory biomarker analysis
Drug · Biological · Procedure + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
3
States / cities
Salt Lake City, Utah • Seattle, Washington • Milwaukee, Wisconsin
Conditions
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Myelodysplastic Syndromes, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Thrombocytopenia
Interventions
flow cytometry, DNA methylation analysis, cytogenetic analysis, decitabine, microarray analysis, gene expression analysis, pharmacological study, polymorphism analysis
Other · Drug · Genetic
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Cleveland, Ohio
Conditions
Breast Cancer
Interventions
comparative genomic hybridization, microarray analysis, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis
Genetic · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Maywood, Illinois
Conditions
Breast Cancer, Cardiac Toxicity
Interventions
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, paclitaxel, gene expression analysis, reverse transcriptase-polymerase chain reaction, fluorophotometry, laboratory biomarker analysis, mass spectrometry, adjuvant therapy, quality-of-life assessment
Biological · Drug · Genetic + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
ipilimumab, cyclophosphamide, biopsy, aldesleukin, immunohistochemistry staining method, polymerase chain reaction, immunoenzyme technique, therapeutic cytotoxic T lymphocytes
Biological · Drug · Procedure + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Breast Cancer
Interventions
gene expression analysis, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis, medical chart review, questionnaire administration
Genetic · Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
50 Years and older · Female only
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Leukemia
Interventions
imatinib mesylate, gene expression analysis, mutation analysis, polymerase chain reaction, flow cytometry, biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
4
States / cities
Buffalo, New York • Durham, North Carolina • Cleveland, Ohio
Conditions
Double-stranded DNA Virus
Interventions
Brincidofovir
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
37
States / cities
Loma Linda, California • Los Angeles, California • Orange, California + 29 more
Conditions
Metastatic Invasive Lobular Carcinoma (mILC)
Interventions
circulating tumor DNA (ctDNA)
Diagnostic Test
Lead sponsor
Julia Foldi
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
polymerase chain reaction, flow cytometry
Genetic · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2006
U.S. locations
40
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 30 more
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Conditions
Sarcoma
Interventions
DNA analysis, gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, immunohistochemistry staining method, laboratory biomarker analysis
Genetic · Other
Lead sponsor
University of Arizona
Other
Eligibility
Not listed
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Covid19, Anxiety, Mood, Cognitive Impairment
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
Head and Neck Cancer
Interventions
microarray analysis, allele-specific oligonucleotide real-time quantitative polymerase chain reaction, diagnostic laboratory biomarker analysis
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Cancer Survivor, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Testicular Germ Cell Tumor
Interventions
DNA analysis, polymerase chain reaction, flow cytometry, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Terminated Phase 2 Interventional Results available

Brivanib Metastatic Renal Cell Carcinoma

NCT01253668
Conditions
Renal Cell Carcinoma
Interventions
Brivanib alaninate, Polymerase chain reaction, Iodine I 124 chimeric monoclonal antibody G250, Positron emission tomography/computed tomography, Protein expression analysis, Immunohistochemistry
Drug · Genetic · Other + 1 more
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Leukemia, Lymphoma
Interventions
filgrastim, pegfilgrastim, rituximab, sargramostim, cyclophosphamide, mitoxantrone hydrochloride, pentostatin, fluorescence in situ hybridization, gene rearrangement analysis, polymerase chain reaction, protein expression analysis, flow cytometry, biopsy
Biological · Drug · Genetic + 2 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
New York, New York